

Lupin launches Testosterone Gel

15 April 2019 | News

It is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone Primary hypogonadism



Lupin has announced the launch of Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), having received an approval from the United States Food and Drug Administration (FDA).

Lupin's Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), is the generic equivalent of AbbVie Inc's AndroGel, 1.62%. It is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone Primary hypogonadism (congenital or acquired) and Hypogonadotropic hypogonadism (congenital or acquired)

Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation) had an annual sales of approximately USD 893 million in the US (IQVIA MAT December 2018).